DOCSLIB.ORG

FTSE Factsheet

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FTSE Factsheet FTSE COMPANY REPORT Share price analysis relative to sector and index performance Ergomed ERGO Pharmaceuticals and Biotechnology — GBP 12.5 at close 14 May 2021 Absolute Relative to FTSE UK All-Share Sector Relative to FTSE UK All-Share Index PERFORMANCE 14-May-2021 14-May-2021 14-May-2021 16 450 300 1D WTD MTD YTD Absolute 5.0 -4.9 -12.6 18.5 14 400 Rel.Sector 4.4 -5.9 -13.9 12.6 250 Rel.Market 3.8 -3.7 -13.2 8.5 350 12 300 200 VALUATION 10 250 Trailing 8 Relative Price Relative Relative Price Relative 150 200 PE 72.0 Absolute Price (local (local currency) AbsolutePrice 6 150 EV/EBITDA 39.3 100 PB 13.2 4 100 PCF 38.9 2 50 50 Div Yield 0.0 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 Price/Sales 8.1 Absolute Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Net Debt/Equity 0.1 100 100 90 Div Payout 0.0 90 90 80 ROE 21.6 80 80 70 70 70 Index) Share Share Sector) Share - - 60 60 60 DESCRIPTION 50 50 50 The Company is a profitable UK-based company, 40 40 40 RSI RSI (Absolute) dedicated to the provision of specialised services to 30 30 30 the pharmaceutical industry and the development of 20 20 new drugs. 10 10 20 RSI (Relative to FTSE UKFTSE All to RSI (Relative RSI (Relative to FTSE UKFTSE All to RSI (Relative 0 0 10 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 May-2020 Aug-2020 Nov-2020 Feb-2021 May-2021 Past performance is no guarantee of future results. Please see the final page for important legal disclosures. 1 of 4 FTSE COMPANY REPORT: Ergomed 14 May 2021 Valuation Metrics Price to Earnings (PE) EV to EBITDA Price to Book (PB) 30-Apr-2021 30-Apr-2021 30-Apr-2021 100 ‖ ‖ ‖ 100 ‖ ‖ 20 80 80 +1SD 15 60 60 +1SD Avg 10 40 40 +1SD Avg -1SD 5 Avg 20 20 -1SD -1SD 0 ‖ ‖ 0 ‖ ‖ 0 May-2016 May-2017 May-2018 May-2019 May-2020 May-2016 May-2017 May-2018 May-2019 May-2020 May-2016 May-2017 May-2018 May-2019 May-2020 PureTech Health 120.0 Oxford Biomedica 100.0 Indivior 18.6 Dechra Pharmaceuticals 120.0 Ergomed 39.3 Ergomed 13.2 Genus 81.7 Genus 36.5 AstraZeneca 8.9 Ergomed 72.0 Dechra Pharmaceuticals 31.5 Oxford Biomedica 8.0 AstraZeneca 40.9 AstraZeneca 20.8 Dechra Pharmaceuticals 6.8 Pharmaceuticals and Biotechnology 21.6 Pharmaceuticals and Biotechnology 12.7 Genus 6.5 Hikma Pharmaceuticals 16.8 Hikma Pharmaceuticals 11.8 Pharmaceuticals and Biotechnology 6.3 GlaxoSmithKline 11.7 Vectura Group 10.9 GlaxoSmithKline 4.6 Vectura Group 5.5 GlaxoSmithKline 8.1 Hikma Pharmaceuticals 3.6 Indivior -9.8 Indivior 7.9 PureTech Health 2.4 Oxford Biomedica -120.0 PureTech Health 0.0 Vectura Group 1.2 -150 -100 -50 0 50 100 150 0 20 40 60 80 100 120 0 2 4 6 8 10 12 14 16 18 20 Price to Cash Flow (PCF) Dividend Yield % Price to Sales (PS) 30-Apr-2021 30-Apr-2021 30-Apr-2021 80 ‖ ‖ ‖ ‖ 1 9 70 0.9 8 0.8 60 +1SD 7 0.7 50 0.6 6 40 0.5 5 Avg +1SD 30 0.4 4 0.3 20 3 Avg 0.2 -1SD 10 0.1 2 0 ‖ ‖ 0 1 -1SD May-2016 May-2017 May-2018 May-2019 May-2020 May-2016 May-2017 May-2018 May-2019 May-2020 May-2016 May-2017 May-2018 May-2019 May-2020 Oxford Biomedica 80.0 GlaxoSmithKline 6.0 PureTech Health 15.0 Genus 48.5 Pharmaceuticals and Biotechnology 3.7 Oxford Biomedica 10.2 Dechra Pharmaceuticals 40.8 AstraZeneca 2.7 Dechra Pharmaceuticals 8.5 Ergomed 38.9 Hikma Pharmaceuticals 1.5 Ergomed 8.1 AstraZeneca 27.0 Dechra Pharmaceuticals 0.9 Genus 6.0 Vectura Group 26.9 Genus 0.6 AstraZeneca 4.9 Hikma Pharmaceuticals 16.8 Vectura Group 0.0 Vectura Group 3.5 Pharmaceuticals and Biotechnology 15.8 PureTech Health 0.0 Pharmaceuticals and Biotechnology 3.2 GlaxoSmithKline 8.8 Oxford Biomedica 0.0 Hikma Pharmaceuticals 3.1 Indivior -7.5 Indivior 0.0 Indivior 2.2 PureTech Health -11.6 Ergomed 0.0 GlaxoSmithKline 2.0 -20 0 20 40 60 80 100 0 1 2 3 4 5 6 7 0 2 4 6 8 10 12 14 16 Note: bar chart reflects the top and bottom five current values for the valuation ratio in question for FTSE All Shares stocks in the same sector as the stock concerned. All valuation metrics are trailing. 2 of 4 FTSE COMPANY REPORT: Ergomed 14 May 2021 Valuation Metrics Net Debt to Equity Dividend Payout (DP) Return on Equity (RoE) 30-Apr-2021 30-Apr-2021 0.15 25 20 0.1 +1SD +1SD 15 10 Avg 0.05 Avg 5 -1SD 0 0 ‖ ‖ May-2016 May-2017 May-2018 May-2019 May-2020 May-2016 May-2017 May-2018 May-2019 May-2020 Indivior 3.5 AstraZeneca 100.0 GlaxoSmithKline 44.2 GlaxoSmithKline 1.9 Dechra Pharmaceuticals 100.0 Pharmaceuticals and Biotechnology 31.8 Pharmaceuticals and Biotechnology 1.5 Pharmaceuticals and Biotechnology 80.5 Vectura Group 25.4 AstraZeneca 1.3 GlaxoSmithKline 69.3 AstraZeneca 23.2 Dechra Pharmaceuticals 0.6 Genus 46.7 Ergomed 21.6 Hikma Pharmaceuticals 0.4 Hikma Pharmaceuticals 26.7 Hikma Pharmaceuticals 21.1 Genus 0.3 Vectura Group 0.0 Genus 8.0 Oxford Biomedica 0.1 PureTech Health 0.0 Dechra Pharmaceuticals 5.9 PureTech Health 0.1 Oxford Biomedica 0.0 PureTech Health 0.9 Ergomed 0.1 Indivior 0.0 Oxford Biomedica -6.6 Vectura Group 0.0 Ergomed 0.0 Indivior -50.0 0 0.5 1 1.5 2 2.5 3 3.5 4 0 20 40 60 80 100 120 -60 -40 -20 0 20 40 60 ROE vs. PB — sector Du Pont Analysis 30-Apr-2021 1.8 25 20 1 INDV 0.9 18 1.6 0.8 1.4 20 16 0.7 0.6 1.2 14 0.5 ERGO 0.4 1 15 12 0.3 0.8 PB 0.2 10 0.1 0.6 10 AZN 0 8 OXB May-2016 May-2017 May-2018 May-2019 May-2020 0.4 DPH GNS 6 Pharmaceuticals 0.2 5 GSK 4 HIK 0 PRTC 2 -0.2 0 VEC ‖ ‖ 2017 2018 2019 2020 2021 0 0 5 10 15 20 25 30 35 40 45 50 Net Margin Asset Turnover Gearing ROE (rhs) ‖ ROE Note: bar chart reflects the top and bottom five current values for the valuation ratio in question for FTSE All Shares stocks in the same sector as the stock concerned. All valuation metrics are trailing. 3 of 4 FTSE COMPANY REPORT: Ergomed 14 May 2021 Brief description Brief description Price to Earnings Price to Earnings (PE) is price over earnings per share. Earnings are based on the latest Gearing Gearing is Total Assets divided by Common Equity. Total Assets and Common Equity are (PE) available fiscal year earnings. each averaged over two years, that is, t and (t-1). Price to Sales (PS) Price to Sales (PS) is price divided by sales per share. It is based on sales from continuing Asset Turnover Asset turnover is Sales divided by Total Assets. Total Assets is averaged over two years, operations for the fiscal year. that is, t and (t-1). Price to Book (PB) Price to Book (PB) is price at the indicated date divided by common equity per share. Dupont Breakdown Return on Equity (RoE) = Net Margin * Gearing * Asset Turnover Common/ordinary equity is generally as reported at the most recent fiscal year-end but is Analysis adjusted to exclude minority interest, preferred stock and selected items as appropriate. RoE vs PB Plot of RoE versus PB at last month end for all FTSE UK All Share stocks in the sector Price to Cash Flow Price to Cash Flow (PCF) is price at the indicated date divided by cash flow per share. relative to the stock in question. Data may be limited to the stock in question if there are (PCF) currently no stocks in the corresponding FTSE UK All Share sector. Net Debt Equity Net Debt Equity is Net Debt as a percentage of common equity. Not calculated if Absolute Absolute graphs reflect performance for the stock in question for up to 366 days adjusted denominator (common equity) is negative for intervening corporate actions. EV to EBITDA EV to EBITDA is Enterprise Value divided by EBITDA (Earnings before Interest and Taxes, Relative Relative charts reflect the performance for the stock in question relative to the depreciation and amortisation). EV is full company Market Capitalisation at the data date corresponding sector of the FTSE All Share Index for up to 366 days, rebased to the start plus last annual net debt and Preferred Stock. Net Debt is total financial debt less cash date. Note that the stock itself may not be a FTSE All share constituent. Relative Chart and short-term investments. EBITDA is operating income plus depreciation and may be null if there are no stocks in the corresponding FTSE UK All Share sector.
Load more

Recommended publications
  • Jefferies 2013 Global Healthcare Conference in London
    Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc.
    [Show full text]
  • March 2018 1 MARKET UPDATE| HEALTHCARE
    MARKET UPDATE| HEALTHCARE MARKET UPDATE HEALTHCARE March 2018 1 MARKET UPDATE| HEALTHCARE HIGHLIGHTS Dear Reader, 2017 ended with the $69 billion CVS Health / Aetna deal. Pharmacy +6.5% Benefit Manager (PBM) consolidation took another major step this month 5Y-CAGR with Cigna scooping up the largest independent PBM, Express Scripts, in a $52 billion deal. Additionally, rumor has it that Walmart is in the early Worldwide stages talks with insurer Humana, looking at a variety of options including prescription drugs - an acquisition. The frenzy might very well be due to Amazon’s debut in expected sales healthcare and the looming shadow of its entrance in the pharmacy market. But Amazon is also putting pressure on consumer care products, intensifying price competition. In response, pharmaceuticals groups are +5.3% parted between those which want to hold on to these products that are 5Y-CAGR generally durable brands with loyal customers, and others which doubt Medtech market - their long-term stable returns. GlaxoSmithKline had us hold our breath: expected growth after entering - and eventually quitting - the race to buy Pfizer’s consumer healthcare business for a price tag hoped to be as much as $20 billion, the company bought Novartis out of their consumer healthcare joint venture for $13 billion. GSK is thus taking full control of products -0.7%/-2.2% including Sensodyne toothpaste, Panadol headache tablets and muscle gel Monthly EU Pharma & Voltaren. biotech performance March was also home to remarkable market transactions in the biotech and medtech fields that had us quite excited, beyond the fact that Bryan, Garnier & Co.
    [Show full text]
  • Factset-Top Ten-0521.Xlsm
    Pax International Sustainable Economy Fund USD 7/31/2021 Port. Ending Market Value Portfolio Weight ASML Holding NV 34,391,879.94 4.3 Roche Holding Ltd 28,162,840.25 3.5 Novo Nordisk A/S Class B 17,719,993.74 2.2 SAP SE 17,154,858.23 2.1 AstraZeneca PLC 15,759,939.73 2.0 Unilever PLC 13,234,315.16 1.7 Commonwealth Bank of Australia 13,046,820.57 1.6 L'Oreal SA 10,415,009.32 1.3 Schneider Electric SE 10,269,506.68 1.3 GlaxoSmithKline plc 9,942,271.59 1.2 Allianz SE 9,890,811.85 1.2 Hong Kong Exchanges & Clearing Ltd. 9,477,680.83 1.2 Lonza Group AG 9,369,993.95 1.2 RELX PLC 9,269,729.12 1.2 BNP Paribas SA Class A 8,824,299.39 1.1 Takeda Pharmaceutical Co. Ltd. 8,557,780.88 1.1 Air Liquide SA 8,445,618.28 1.1 KDDI Corporation 7,560,223.63 0.9 Recruit Holdings Co., Ltd. 7,424,282.72 0.9 HOYA CORPORATION 7,295,471.27 0.9 ABB Ltd. 7,293,350.84 0.9 BASF SE 7,257,816.71 0.9 Tokyo Electron Ltd. 7,049,583.59 0.9 Munich Reinsurance Company 7,019,776.96 0.9 ASSA ABLOY AB Class B 6,982,707.69 0.9 Vestas Wind Systems A/S 6,965,518.08 0.9 Merck KGaA 6,868,081.50 0.9 Iberdrola SA 6,581,084.07 0.8 Compagnie Generale des Etablissements Michelin SCA 6,555,056.14 0.8 Straumann Holding AG 6,480,282.66 0.8 Atlas Copco AB Class B 6,194,910.19 0.8 Deutsche Boerse AG 6,186,305.10 0.8 UPM-Kymmene Oyj 5,956,283.07 0.7 Deutsche Post AG 5,851,177.11 0.7 Enel SpA 5,808,234.13 0.7 AXA SA 5,790,969.55 0.7 Nintendo Co., Ltd.
    [Show full text]
  • Annex 1: Parker Review Survey Results As at 2 November 2020
    Annex 1: Parker Review survey results as at 2 November 2020 The data included in this table is a representation of the survey results as at 2 November 2020, which were self-declared by the FTSE 100 companies. As at March 2021, a further seven FTSE 100 companies have appointed directors from a minority ethnic group, effective in the early months of this year. These companies have been identified through an * in the table below. 3 3 4 4 2 2 Company Company 1 1 (source: BoardEx) Met Not Met Did Not Submit Data Respond Not Did Met Not Met Did Not Submit Data Respond Not Did 1 Admiral Group PLC a 27 Hargreaves Lansdown PLC a 2 Anglo American PLC a 28 Hikma Pharmaceuticals PLC a 3 Antofagasta PLC a 29 HSBC Holdings PLC a InterContinental Hotels 30 a 4 AstraZeneca PLC a Group PLC 5 Avast PLC a 31 Intermediate Capital Group PLC a 6 Aveva PLC a 32 Intertek Group PLC a 7 B&M European Value Retail S.A. a 33 J Sainsbury PLC a 8 Barclays PLC a 34 Johnson Matthey PLC a 9 Barratt Developments PLC a 35 Kingfisher PLC a 10 Berkeley Group Holdings PLC a 36 Legal & General Group PLC a 11 BHP Group PLC a 37 Lloyds Banking Group PLC a 12 BP PLC a 38 Melrose Industries PLC a 13 British American Tobacco PLC a 39 Mondi PLC a 14 British Land Company PLC a 40 National Grid PLC a 15 BT Group PLC a 41 NatWest Group PLC a 16 Bunzl PLC a 42 Ocado Group PLC a 17 Burberry Group PLC a 43 Pearson PLC a 18 Coca-Cola HBC AG a 44 Pennon Group PLC a 19 Compass Group PLC a 45 Phoenix Group Holdings PLC a 20 Diageo PLC a 46 Polymetal International PLC a 21 Experian PLC a 47
    [Show full text]
  • Constituents & Weights
    2 FTSE Russell Publications 19 August 2021 FTSE 100 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Group 0.59 UNITED GlaxoSmithKline 3.7 UNITED RELX 1.88 UNITED KINGDOM KINGDOM KINGDOM Admiral Group 0.35 UNITED Glencore 1.97 UNITED Rentokil Initial 0.49 UNITED KINGDOM KINGDOM KINGDOM Anglo American 1.86 UNITED Halma 0.54 UNITED Rightmove 0.29 UNITED KINGDOM KINGDOM KINGDOM Antofagasta 0.26 UNITED Hargreaves Lansdown 0.32 UNITED Rio Tinto 3.41 UNITED KINGDOM KINGDOM KINGDOM Ashtead Group 1.26 UNITED Hikma Pharmaceuticals 0.22 UNITED Rolls-Royce Holdings 0.39 UNITED KINGDOM KINGDOM KINGDOM Associated British Foods 0.41 UNITED HSBC Hldgs 4.5 UNITED Royal Dutch Shell A 3.13 UNITED KINGDOM KINGDOM KINGDOM AstraZeneca 6.02 UNITED Imperial Brands 0.77 UNITED Royal Dutch Shell B 2.74 UNITED KINGDOM KINGDOM KINGDOM Auto Trader Group 0.32 UNITED Informa 0.4 UNITED Royal Mail 0.28 UNITED KINGDOM KINGDOM KINGDOM Avast 0.14 UNITED InterContinental Hotels Group 0.46 UNITED Sage Group 0.39 UNITED KINGDOM KINGDOM KINGDOM Aveva Group 0.23 UNITED Intermediate Capital Group 0.31 UNITED Sainsbury (J) 0.24 UNITED KINGDOM KINGDOM KINGDOM Aviva 0.84 UNITED International Consolidated Airlines 0.34 UNITED Schroders 0.21 UNITED KINGDOM Group KINGDOM KINGDOM B&M European Value Retail 0.27 UNITED Intertek Group 0.47 UNITED Scottish Mortgage Inv Tst 1 UNITED KINGDOM KINGDOM KINGDOM BAE Systems 0.89 UNITED ITV 0.25 UNITED Segro 0.69 UNITED KINGDOM
    [Show full text]
  • RCP BIA 2020 Review January 2021 FINAL.Pdf
    UK BioIndustry Association UK Listed Biotech & Life Sciences 2020 – Year in Review– May you live in interesting times Radnor Broad UK Listed Biotech Index - 2 Year Chart Unweighted Weighted FTSE All-Share 350 300 250 200 150 100 50 Dec '20 Dec Dec '18 Dec '19 Mar '19 Jun '19 Sep '19 Dec '20 Mar '20 Jun '20 Sep Source: FactSet, Radnor 2020 has been an extraordinary year across the market but there is no doubt that the UK listed biotech sector has been in the front line in more ways than one. Investors have clearly responded to both the efforts made by the sector to combat the pandemic, but also the structural growth opportunity within biotech that the pandemic has bought into sharper focus. Not only have we seen headline share price underperformance reverse sharply through the course of 2020, but critically, the pace and scale of sector fundraising activity has stepped up materially. Perhaps most importantly, the number of investors active in the sector (institutional, private wealth, individual and overseas) have expanded. This feature alone has gone a long way towards addressing one of the key issues facing the sector. The BioIndustry Association ▪ Sector Outperformance. 2020 has been the strongest period of price is a research client of Radnor outperformance over the last 10 years. Interestingly, this outperformance has Capital Partners Ltd. been delivered across all the sub-indices making up the Broad Biotech index; although performance levels have varied somewhat. This outperformance has MiFID II – this research is also been much more pronounced then looking at the sector on an equal deemed to be a minor, non- monetary benefit.
    [Show full text]
  • Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP
    Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767%
    [Show full text]
  • Oxford Biomedica Delivering Commercial Gene-Therapy Vector
    31st March 2017 Pharmaceuticals & Biotechnology Oxford BioMedica Delivering commercial gene-therapy vector OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties Source: Fidessa on commercial products developed with its LentiVector® platform: extensive IP, facilities, and know-how for production and development of lentiviral vectors to Market data generate gene-based therapies. OXB intends to out-license its five clinical EPIC/TKR OXB candidates and to continue investment in R&D. Bioprocessing royalties are likely Price (p) 5.2 to result in significant upside potential in the near future. 12m High (p) 6.5 12m Low (p) 3.0 ► Strategy: Oxford BioMedica has four strategic objectives: delivery of process Shares (m) 3,088.2 development services which embed its technology in partners’ commercial Mkt Cap (£m) 159.0 products; commercial manufacture of lentiviral vector; out-licensing of EV (£m) 178.1 proprietary candidates; and investment in R&D and the LentiVector platform. Free Float 65% Market LSE ► Revenues: Bioprocessing and process development command fees-for-service, with process development also incurring upfront, milestone and incentive Description payments plus licensing income and royalties on commercial products. Out- Oxford BioMedica is a UK-based licensed candidates will deliver licensing fees plus high royalties if successful. biopharmaceutical company specializing in cell and gene therapies developed using lentiviral vectors, ► Valuation: An EV/sales multiple of 4x prospective sales for the bioprocessing gene-delivery vehicles based on virus and process development services is readily justified, which generates a value particles.
    [Show full text]
  • Spec Pharma M&A Transaction Multiples
    SECTOR REPORT FOURTH QUARTER 2016 Disclaimer All information set forth in this report (the “Overview”) has been synthesized by Bourne Capital Partners, L.L.C. (“BP”) or was obtained from publicly available sources. BP makes no express or implied representation or warranty as to the accuracy or completeness of the information contained herein. BP expressly disclaims any and all liability that may be based on all information set forth in the Overview, errors therein, or omissions therefrom. This Overview includes certain statements, estimates and projections provided by BP with respect to anticipated future performance. Such statements, estimates and projections reflect various assumptions made by BP concerning anticipated results, which reflect significant subjective judgments made by BP and as a result, may or may not prove to be correct. There can be no assurance that such projected results are attainable or will be realized. No express or implied representations or warranties are made as to the accuracy of such statements, estimates or projections. In furnishing the Overview, BP does not undertake any obligation to provide the recipient with access to any additional information, to correct any inaccuracies that may become apparent or to update or otherwise revise this Overview. This Overview is not an offer to sell or a solicitation of an offer to purchase securities or to engage in any other transaction. BP is a North Carolina (USA) limited liability company doing business as Bourne Partners with divisions in Healthcare Merchant Banking, Alternative Assets, Management Consulting and Investment Banking. Investment Banking services are offered by Bourne Partners Securities, LLC, a registered broker dealer, Member FINRA and SIPC.
    [Show full text]
  • FTSE Russell Publications
    2 FTSE Russell Publications 19 August 2021 FTSE 250 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Infrastructure 0.43 UNITED Bytes Technology Group 0.23 UNITED Edinburgh Investment Trust 0.25 UNITED KINGDOM KINGDOM KINGDOM 4imprint Group 0.18 UNITED C&C Group 0.23 UNITED Edinburgh Worldwide Inv Tst 0.35 UNITED KINGDOM KINGDOM KINGDOM 888 Holdings 0.25 UNITED Cairn Energy 0.17 UNITED Electrocomponents 1.18 UNITED KINGDOM KINGDOM KINGDOM Aberforth Smaller Companies Tst 0.33 UNITED Caledonia Investments 0.25 UNITED Elementis 0.21 UNITED KINGDOM KINGDOM KINGDOM Aggreko 0.51 UNITED Capita 0.15 UNITED Energean 0.21 UNITED KINGDOM KINGDOM KINGDOM Airtel Africa 0.19 UNITED Capital & Counties Properties 0.29 UNITED Essentra 0.23 UNITED KINGDOM KINGDOM KINGDOM AJ Bell 0.31 UNITED Carnival 0.54 UNITED Euromoney Institutional Investor 0.26 UNITED KINGDOM KINGDOM KINGDOM Alliance Trust 0.77 UNITED Centamin 0.27 UNITED European Opportunities Trust 0.19 UNITED KINGDOM KINGDOM KINGDOM Allianz Technology Trust 0.31 UNITED Centrica 0.74 UNITED F&C Investment Trust 1.1 UNITED KINGDOM KINGDOM KINGDOM AO World 0.18 UNITED Chemring Group 0.2 UNITED FDM Group Holdings 0.21 UNITED KINGDOM KINGDOM KINGDOM Apax Global Alpha 0.17 UNITED Chrysalis Investments 0.33 UNITED Ferrexpo 0.3 UNITED KINGDOM KINGDOM KINGDOM Ascential 0.4 UNITED Cineworld Group 0.19 UNITED Fidelity China Special Situations 0.35 UNITED KINGDOM KINGDOM KINGDOM Ashmore
    [Show full text]
  • We Deliver Accurate, High-Quality and Timely Information to All Stakeholders with the Utmost Integrity and Efficiency
    We deliver accurate, high-quality and timely information to all stakeholders with the utmost integrity and efficiency. 107 Independent auditors’ report 115 Consolidated financial statements 120 Notes to the Consolidated financial statements 168 Company financial statements 170 Notes to the Company financial statements Financial statements 106 Hikma Pharmaceuticals PLC | Annual Report 2019 Independent auditors’ report to the members of Hikma Pharmaceuticals PLC Report on the audit of the financial statements Separate opinion in relation to IFRSs as issued by the IASB Opinion As explained in note 2 to the financial statements, the Group, in In our opinion: addition to applying IFRSs as adopted by the European Union, has also applied IFRSs as issued by the International Accounting Standards — Hikma Pharmaceuticals PLC ’s Group financial statements and Board (IASB). Company financial statements (the “financial statements”) give a true and fair view of the state of the Group’s and of the Company’s affairs In our opinion, the Group financial statements have been properly as at 31 December 2019 and of the Group’s profit and cash flows for prepared in accordance with IFRSs as issued by the IASB. the year then ended; — the Group financial statements have been properly prepared in Basis for opinion accordance with International Financial Reporting Standards (IFRSs) We conducted our audit in accordance with International Standards on as adopted by the European Union; Auditing (UK) (“ISAs (UK)”) and applicable law. Our responsibilities — the Company financial statements have been properly prepared in under ISAs (UK) are further described in the Auditors’ responsibilities accordance with United Kingdom Generally Accepted Accounting for the audit of the financial statements section of our report.
    [Show full text]
  • Witan Investment Trust Plc Portfolio Listing As at 31.07.2021
    WITAN INVESTMENT TRUST PLC PORTFOLIO LISTING AS AT 31.07.2021 SECURITY % OF TOTAL INVESTMENT APAX GBL ALPHA NPV 2.98 ALPHABET A USD0.001 1.88 PRINCESS PRIVATE EQTY HLDGS ORD EUR0.001 1.87 ELECTRA PRIVATE GBP 0.25 1.53 SYNCONA ORD NPV 1.34 CHARTER COMMUNICATIONS -A USD0.001 1.32 BLACKROCK WORLD MINING TST ORD GBP0.05 1.31 ARCELORMITTAL NPV 1.30 DIAGEO GBP28.93518 1.27 PAYPAL HLDGS USD0.0001 1.16 INTUIT USD0.01 1.11 HEINEKEN HLDGS EUR1.6 1.08 SCHRODER REAL ESTATE INV TST ORD NPV 1.03 THERMO FISHER SCIENTIFIC USD1 1.02 UNILEVER GBP0.031111 1.00 BT GRP ORD GBP0.05 0.98 NATWEST GRP GBP1 0.91 TAIWAN SEMICONDUCTOR MANUFACTURING 1 ADS REP 5 ORD TWD10 0.89 FACEBOOK A USD0.000006 0.89 FREEPORT-MCMORAN USD0.1 0.89 RELX GBP0.144397 0.86 NATL GRID ORD GBP0.12431289 0.85 LLOYDS BANKING GRP GBP0.1 0.85 VIVENDI EUR5.5 0.82 WALT DISNEY CO USD0.01 0.82 LINDENWOOD USD 0.81 BAE SYSTEMS ORD GBP0.025 0.80 MICROSOFT CORP USD0.00000625 0.79 SHOPIFY A NPV 0.79 CANADIAN PACIFIC RAILWAY NPV 0.77 VINCI EUR2.5 0.77 LONDON STK EXCHANGE GRP GBP0.06918605 0.76 SMURFIT KAPPA GRP EUR0.001 0.76 UNITEDHEALTH GRP USD0.01 0.75 PEPSICO USD0.017 0.74 MONDELEZ INTL USD0.01 0.74 PEARSON GBP0.25 0.70 NINTENDO CO NPV 0.69 LVMH MOET HENNESSY LOUIS VUI EUR0.3 0.68 VH GBL SUSTAINABLE ENERGY NPV 0.67 MOODYS CORP USD0.01 0.67 CRH EUR0.32 0.66 FISERV USD0.01 0.66 LAM RESEARCH CORP COM USD0.001 0.65 BREEDON GRP NPV 0.64 FLUTTER ENT GBP0.09 0.63 SHISEIDO CO NPV 0.63 COOPER COS COM USD0.10 0.63 MASTERCARD A USD0.0001 0.62 MERCADOLIBRE COM USD0.001 0.61 BECTON DICKINSON & CO USD1 0.59 SAFRAN EUR0.20 0.58 ILLUMINA COM USD0.01 0.58 PRYSMIAN EUR NPV 0.57 BAXTER INTL COM USD1 0.56 DELTA AIR LINES USD0.0001 0.55 APPLIED MATERIALS USD0.01 0.55 STRYKER CORP USD0.1 0.54 HARGREAVES LANSDOWN GBP0.004 0.54 SONIC HEALTHCARE NPV 0.53 ADYEN NPV 0.53 CATALENT USD0.01 0.52 WEST PHARMACEUTICAL SERV USD0.25 0.51 INTERCONTINENTAL EXCHANGE GRP USD0.01 0.50 KAO CORP NPV 0.50 TAIWAN SEMICONDUCTOR MANUFACTURING TWD10 0.48 EBAY USD0.001 0.48 REMY COINTREAU EUR1.6 0.48 Please see the disclaimer at the end of this document.
    [Show full text]